HC Wainwright Issues Optimistic Estimate for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – HC Wainwright lifted their Q3 2026 earnings per share estimates for Mirum Pharmaceuticals in a report released on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.31) per share for the quarter, up from their previous estimate of ($1.06). HC Wainwright currently has a “Buy” rating and a $140.00 price target on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($4.42) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.40 EPS, Q4 2027 earnings at $0.64 EPS, FY2027 earnings at $1.28 EPS, FY2028 earnings at $3.96 EPS, FY2029 earnings at $5.71 EPS and FY2030 earnings at $7.12 EPS.

MIRM has been the topic of a number of other reports. TD Cowen lowered their price target on shares of Mirum Pharmaceuticals from $145.00 to $140.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Stifel Nicolaus set a $136.00 price objective on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Citigroup reissued an “outperform” rating on shares of Mirum Pharmaceuticals in a research note on Thursday. Evercore restated an “outperform” rating and set a $138.00 target price on shares of Mirum Pharmaceuticals in a report on Thursday, May 7th. Finally, Robert W. Baird set a $123.00 price target on Mirum Pharmaceuticals in a research report on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.33.

Mirum Pharmaceuticals Price Performance

Shares of NASDAQ MIRM opened at $98.70 on Monday. The firm has a 50-day simple moving average of $110.38 and a 200-day simple moving average of $101.91. The stock has a market capitalization of $6.41 billion, a price-to-earnings ratio of -6.78 and a beta of 0.52. The company has a quick ratio of 2.74, a current ratio of 2.86 and a debt-to-equity ratio of 1.28. Mirum Pharmaceuticals has a 52 week low of $58.48 and a 52 week high of $130.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last announced its earnings results on Wednesday, August 5th. The company reported ($1.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.32). Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The business had revenue of $176.24 million for the quarter, compared to analyst estimates of $166.33 million. During the same period last year, the firm earned ($0.12) EPS. The company’s revenue for the quarter was up 37.9% compared to the same quarter last year.

Insider Buying and Selling

In other Mirum Pharmaceuticals news, SVP Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $105.29, for a total transaction of $193,733.60. Following the transaction, the senior vice president directly owned 1,274 shares of the company’s stock, valued at $134,139.46. The trade was a 59.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $122.27, for a total transaction of $2,445,400.00. Following the transaction, the chief executive officer directly owned 194,309 shares in the company, valued at $23,758,161.43. This trade represents a 9.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 67,155 shares of company stock worth $7,185,662. Insiders own 8.32% of the company’s stock.

Institutional Investors Weigh In On Mirum Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MIRM. BlackRock Inc. purchased a new position in Mirum Pharmaceuticals during the second quarter worth about $513,945,000. Janus Henderson Group PLC raised its stake in shares of Mirum Pharmaceuticals by 21.4% in the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock valued at $479,050,000 after acquiring an additional 1,067,722 shares during the period. State Street Corp raised its stake in shares of Mirum Pharmaceuticals by 59.2% in the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock valued at $169,354,000 after acquiring an additional 797,088 shares during the period. Wellington Management Group LLP lifted its holdings in shares of Mirum Pharmaceuticals by 566.8% in the 3rd quarter. Wellington Management Group LLP now owns 790,689 shares of the company’s stock worth $57,965,000 after acquiring an additional 672,118 shares during the last quarter. Finally, Bank of New York Mellon Corp acquired a new position in shares of Mirum Pharmaceuticals in the 2nd quarter worth approximately $78,434,000.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.